TOPORS E3 ligase mediates resistance to hypomethylating agent cytotoxicity in acute myeloid leukemia cells-Reference-Cited by-同舟云学术

TOPORS E3 ligase mediates resistance to hypomethylating agent cytotoxicity in acute myeloid leukemia cells

Published:2024-08-28 Issue:1 Volume:15 Page:
ISSN:2041-1723
Container-title:Nature Communications
language:en
Short-container-title:Nat Commun

Author:

Truong Peter^ORCID,Shen Sylvie,Joshi Swapna,Islam Md Imtiazul,Zhong Ling,Raftery Mark J.,Afrasiabi Ali,Alinejad-Rokny Hamid^ORCID,Nguyen Mary,Zou Xiaoheng,Bhuyan Golam Sarower,Sarowar Chowdhury H.,Ghodousi Elaheh S.,Stonehouse Olivia^ORCID,Mohamed Sara,Toscan Cara E.,Connerty Patrick,Kakadia Purvi M.,Bohlander Stefan K.^ORCID,Michie Katharine A.^ORCID,Larsson Jonas^ORCID,Lock Richard B.,Walkley Carl R.^ORCID,Thoms Julie A. I.^ORCID,Jolly Christopher J.,Pimanda John E.^ORCID

Funder

Department of Health | National Health and Medical Research Council

Cancer Institute NSW

Publisher

Springer Science and Business Media LLC

Link

https://www.nature.com/articles/s41467-024-51646-6.pdf

Reference79 articles.

1. Fenaux, P. et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 10, 223–232 (2009).

2. Prébet, T. et al. Outcome of high-risk myelodysplastic syndrome after azacitidine treatment. Fail. J. Clin. Oncol. 29, 3322–3327 (2011).

3. Saunthararajah, Y. et al. Evaluation of noncytotoxic DNMT1-depleting therapy in patients with myelodysplastic syndromes. J. Clin. Invest. 125, 1043–1055 (2015).

4. Steensma, D. P. et al. Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT). trial J. Clin. Oncol. 27, 3842–3848 (2009).

5. Gu, X. et al. Decitabine- and 5-azacytidine resistance emerges from adaptive responses of the pyrimidine metabolism network. Leukemia 35, 1023–1036 (2020).